Biomarker-Based Lung Cancer Screening Eligibility: Implementation Considerations.
Rayjean J HungPublished in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2022)
With the convergence of promising biomarkers for lung cancer risk stratifications, and the increasing need for better eligibility assessment for lung cancer low-dose CT (LDCT) screening, the elephant in the room now is whether and how the implementation of biomarker-based lung cancer screening eligibility can be successfully achieved. This brief commentary provides an outline of key considerations for biomarker implementations for LDCT eligibility assessment and possible mitigation strategies. See related article by Jacobsen et al., p. 758.